Kexing Biopharm (688136.SH): Clinical Trial Registration Application for GB10 Injection Receives Regulatory Acceptance

Stock News2025-09-29

Kexing Biopharm Co.,Ltd. (688136.SH) announced that its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd. ("Shenzhen Kexing"), has recently received an "Acceptance Notice" administrative licensing document from the National Medical Products Administration (NMPA). The company's clinical trial application for "GB10 Injection" has been officially accepted for review.

The regulatory acceptance of the GB10 injection clinical trial application represents a significant milestone in the company's innovative drug development pipeline. This development marks crucial progress in Kexing Biopharm's bispecific antibody research and development strategy based on its proprietary technology platform. Should the drug development prove successful and achieve future market approval, it would provide more diversified product options to meet market demand, helping to enrich the company's product portfolio and further enhance its market competitiveness.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1181034097?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-29 17:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181034097","market":"sg","top_or_hot":-1,"title":"Kexing Biopharm (688136.SH): Clinical Trial Registration Application for GB10 Injection Receives Regulatory Acceptance","media":"Stock News","content":"<p>Kexing Biopharm Co.,Ltd. (688136.SH) announced that its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd. (\"Shenzhen Kexing\"), has recently received an \"Acceptance Notice\" administrative licensing document from the National Medical Products Administration (NMPA). The company's clinical trial application for \"GB10 Injection\" has been officially accepted for review.</p>\n<p>The regulatory acceptance of the GB10 injection clinical trial application represents a significant milestone in the company's innovative drug development pipeline. This development marks crucial progress in Kexing Biopharm's bispecific antibody research and development strategy based on its proprietary technology platform. Should the drug development prove successful and achieve future market approval, it would provide more diversified product options to meet market demand, helping to enrich the company's product portfolio and further enhance its market competitiveness.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kexing Biopharm (688136.SH): Clinical Trial Registration Application for GB10 Injection Receives Regulatory Acceptance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKexing Biopharm (688136.SH): Clinical Trial Registration Application for GB10 Injection Receives Regulatory Acceptance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-29 17:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Kexing Biopharm Co.,Ltd. (688136.SH) announced that its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd. (\"Shenzhen Kexing\"), has recently received an \"Acceptance Notice\" administrative licensing document from the National Medical Products Administration (NMPA). The company's clinical trial application for \"GB10 Injection\" has been officially accepted for review.</p>\n<p>The regulatory acceptance of the GB10 injection clinical trial application represents a significant milestone in the company's innovative drug development pipeline. This development marks crucial progress in Kexing Biopharm's bispecific antibody research and development strategy based on its proprietary technology platform. Should the drug development prove successful and achieve future market approval, it would provide more diversified product options to meet market demand, helping to enrich the company's product portfolio and further enhance its market competitiveness.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688136","symbol_name":"科兴制药","start_time":0,"source_url":"","article_id":"1181034097","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181034097","pubTimestamp":1759138837,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Kexing Biopharm Co.,Ltd. (688136.SH) announced that its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd. (\"Shenzhen Kexing\"), has recently received an \"Acceptance Notice\"...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688136":"科兴制药","BK0239":"医药制造"},"translate_title":"科兴生物（688136.SH）：GB10注射液临床试验注册申请获监管受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688136":1},"content_text":"Kexing Biopharm Co.,Ltd. (688136.SH) announced that its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd. (\"Shenzhen Kexing\"), has recently received an \"Acceptance Notice\" administrative licensing document from the National Medical Products Administration (NMPA). The company's clinical trial application for \"GB10 Injection\" has been officially accepted for review.\nThe regulatory acceptance of the GB10 injection clinical trial application represents a significant milestone in the company's innovative drug development pipeline. This development marks crucial progress in Kexing Biopharm's bispecific antibody research and development strategy based on its proprietary technology platform. Should the drug development prove successful and achieve future market approval, it would provide more diversified product options to meet market demand, helping to enrich the company's product portfolio and further enhance its market competitiveness.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1181034097","isCrawlerRequest":true}